yes i agree - who knows next 18 months could even bare multiple fruit if luck runs our way. i note Dirk touched on possibility of a licence for the calimmune programme.
"Benitec license?
Benitec, of course, will follow Calimmune's developments with great interest as the company has rights to critical ddRNAi trigger patents. Curiously, both companies are based in Australia, but have significant roots also in the US South-West, so it should be possible to come to an amicable agreement.
License or not, it will be good for the entire field of RNAi Therapeutics, and ddRNAi Therapeutics in particular, for this trial to get underway in 2012 as it should attract significant general interest to a what looks like a solid RNAi Therapeutics candidate."
BLT Price at posting:
70.0¢ Sentiment: Buy Disclosure: Held
